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1 Report of an International Workshop at the Gene Center of Munich, Ger-
many, September 9–10, 1999.
Abbreviations used in this paper
EG embryonic germ
ERK extracellular signal-regulated kinase
ES embryonic stem
gp glycoprotein
ICM inner cell mass
JAK Janus kinase
LIFR leukemia inhibitory factor receptor
MAPK mitogen-activated protein kinase
MEK MAP/ERK kinase
MPF mitosis-promoting factor
PG primordial germ
STAT signal transducer and activator of transcription
Technological advances of the last 2 years in mamma-
lian nuclear transfer techniques [Wilmut et al., 1997] and
in the establishment of human embryonic stem cell lines
[Shamblott et al., 1998; Thomson et al., 1998] formed the
background of the International Workshop on ‘Em-
bryonic Stem Cells and Nuclear Transfer Strategies’ orga-
nized at the Gene Center, Munich, September 1999. The
aim of the meeting was to bring together scientists work-
ing in the stem cell field and those working on somatic
nuclear transfer techniques to discuss the present state
and prospects of both technologies for basic and applied
research and future use in medicine and livestock breed-
ing. ‘Biology of embryonic stem cells’, ‘Nuclear transfer
strategies’ and ‘Stem cell differentiation – Cell therapy’
covered the main topics of the meeting.
It became clear that we are far away from understand-
ing the processes involved in stem cell self-renewal and
differentiation as well as the mechanisms resulting in
reprogramming of nuclei from somatic cells after transfer
into enucleated oocytes. However, data were presented
which showed the enormous potential of the embryonic
stem cell technology for tissue transplantation in the
future. About 150 participants from Germany, European
countries, and from the United States participated in the
meeting.
In his opening lecture ‘The oocyte – the ultimate stem
cell’ Jonathan Van Blerkom (University of Colorado,
USA) demonstrated and discussed the oocyte contribu-
tions to embryonic development. Unique protein do-
mains, concentration gradients, asymmetric protein dis-
tributions and polarities are principal forces establishing
the identity and fate of individual blastomeres or cells
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during early development in most of the investigated spe-
cies. Van Blerkom and his coworkers [Antczak and Van
Blerkom, 1997, 1999] showed that these same principles
exist during mammalian and human early development
in the form of at least two representative regulatory pro-
teins, leptin and STAT3. Analysis of leptin and STAT3 in
intact ovarian follicles before ovulation suggested that
these proteins are maternally derived and, in particular,
that a subpopulation of epithelial follicle cells could be
partly responsible for the establishment of their polarized
distribution in the oocyte. Detailed investigation of the
vascularization and perfusion of individual ovarian folli-
cles revealed a significant difference in these vital alimen-
tations from one follicle to another. Follow-up of the
developmental capacity of individual oocytes after follicle
puncture and in vitro fertilization demonstrated a highly
positive correlation between poorly nourished follicles
and defective early embryonic development [Van Bler-
kom, 1998]. Further parameters of polarized cytoplasmic
organization of the oocyte were demonstrated by the local
concentration of mitochondria around the two pronuclei
forming a ‘doughnut-like’ ring around these two charac-
teristically arranged and allocated nuclei of the fertilized
oocyte. Allocation of mitochondria may be of significance
still in blastomeres, because mitochondria-free blasto-
meres undergo fragmentation. These fascinating results of
oocyte and cleavage stage cytoplasmic organization were
discussed with respect to the proposition that polarized
location of proteins and cytoplasmic organelles may have
critical roles in early embryonic development and may be
also involved in the determination of the animal pole of
the oocyte as well as in the establishment of the inner cell
mass and trophoblast in the mammalian preimplantation
stage embryo.
In the first session ‘Biology of embryonic stem cells’,
Austin Smith (Centre for Genome Research, Edinburgh,
UK) presented an overview on the control of stem cell
proliferation and differentiation. Self-renewal of undiffer-
entiated mouse ES cells is regulated by a LIFR/gp130 sig-
naling complex. LIF binds to LIFR and gp130, thereby
activating the receptor-associated JAK kinases. Subse-
quent JAK activation and phosphorylation of receptor
tyrosines leads to stimulation of both the STAT and
MAPK signaling pathways [Niwa et al., 1998]. There were
several lines of evidence that ERK activation is involved
in early embryonic differentiation. However, pretreat-
ment of ES cells with PD098059, an inhibitor of ERK-
mediating MEK enzymes, did not impair ES cell self-
renewal. Several possibilities by which STAT3 activity
may block ES cell differentiation have been discussed: (i)
activation of genes maintaining pluripotency (i.e. Oct-4);
(ii) influence on cell cycle progression; (iii) regulation of
genes involved in growth control, or (iv) blocking the
activity of signals that direct differentiation. At present, a
mechanism of stem cell regulation is discussed which
involves a coordinated balance between STAT versus
ERK signaling pathways to regulate self-renewal and dif-
ferentiation: STAT3 may act by repressing transcription
of differentiation genes, whereas ERK-dependent factors
may induce their expression [Burdon et al., 1999].
Oct-4, a transcription factor of the POU family is
another important factor maintaining totipotency or plu-
ripotency, respectively, of embryonic cells at early devel-
opmental stages (i.e. zygotes, blastomeres, ICM, em-
bryonic ectoderm, primordial germ cells) [Pesce et al.,
1999]. Hans Schöler (EMBL, Heidelberg; now University
of Pennsylvania, Philadelphia, Pa., USA) summarized the
present knowledge of the molecular and cellular functions
of Oct-4. It is suggested that not only leptin/STAT3 pro-
teins are located in a highly polarized, asymmetric distri-
bution, but also Oct-4 might be regulated in a position-
dependent manner in the early embryo. The finding that
Oct-4-deficient embryos died shortly after implantation
due to a lack of ICM development demonstrated that Oct-
4 plays an important role in the development of early
embryos. Oct-4 loss of function caused embryonic cells to
exit the totipotent cycle when the first lineage decision
occurred in the embryo. The analysis of transgenic mice
in which LacZ reporter genes were expressed under the
control of different parts of the Oct-4 regulatory region
provided evidence for two distinct enhancers located
upstream of the promoter. Further work has to show how
these enhancers and cis-acting elements within the en-
hancers (or other regions of the gene) regulate the expres-
sion of Oct-4 in totipotent cells. The germ-line compe-
tence and Oct-4 expression in primordial germ (PG) cells
is another aspect. In this context it is suggested that the
extraembryonic localization of PG cells may protect them
from Oct-4 downregulation, in a way that the positional
information may be involved in the regulation of gene
function via inductive signals. It was found that a ‘switch’
in the activity from the Oct-4 proximal enhancer to the
distal enhancer temporally and spatially coincided with
the location of PG cells suggesting that the ‘reprogram-
ming’ of Oct-4 expression in PG cells may be under the
control of the same signal. In this view, the segregation of
Oct-4 expressing cells in the extra-embryonic mesoderm
of mouse embryos would mean that germ-line competent
cells escape from differentiation-inducing signals and
maintain a totipotent (or pluripotent) phenotype.
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Another important problem discussed at the meeting
was the developmental potential of blastocyst-derived ES
versus PG cell-derived EG cells introduced by Azim
Surani (Wellcome, CRC Institute, Cambridge, UK) in his
lecture on ‘Nuclear reprogramming and imprinting in the
germ line’.
Functional differences exist between parental genomes
during mouse development because of the differential
expression of imprinted genes. In addition, differences in
allele-specific methylation and X-chromosome inactiva-
tion distinguish the germ cell lineage from somatic cells
[Surani, 1999]. Germ cells are essentially devoid of ga-
metic imprints. To test how the imprint-free PG cell
nucleus affects development, nuclei from male PG cells
from day E14.5 to day E16.5 of the fetal gonad were trans-
planted into enucleated oocytes. The reconstructed em-
bryos developed until day 9.5 of gestation, but displayed
reduced size and abnormalities of the placenta suggesting
that gametic imprints are essential for normal develop-
ment [Kato et al., 1999]. These findings point to an
important factor in the discussion on the use of preim-
plantation embryos versus fetal PG cells for the isolation
of human pluripotent cells, providing the basis for cell
therapy. Given the fact that many genes (about 40 identi-
fied genes) are paternally or maternally imprinted and are
important for cellular function and behavior [Li et al.,
1999], it may be difficult to use PG cells from fetuses
equivalent to ES cells from embryos [Steghaus-Kovacs,
1999]. In this respect, the stage of development at which
the PG cells are isolated and cultivated as embryonic
germ cell lines seems to be critical.
The second part of the meeting, ‘Nuclear transfer strat-
egies’, was covered by Keith Campbell (PPL Therapeu-
tics, Roslin, UK) and Jose B. Cibelli (Advanced Cell
Technology, Worcester, Mass., USA). Keith Campbell
gave an overview over the technical considerations that
had to be taken to finally succeed in producing live lambs
from cultured cells by nuclear transfer [Campbell et al.,
1996b]. Nuclear transfer requires a suitable constellation
between stage of cell cycle of donor cell and recipient cyto-
plasm resulting in successful re-programming of gene
expression and correct ploidy of the reconstructed em-
bryo. When oocytes with high MPF activity are used as
recipients, normal diploid embryos result only after trans-
fer of nuclei in G1. When using nuclei in the S phase, the
chromatin is pulverized during premature chromatin con-
densation, whereas G2 nuclei give rise to tetraploid em-
bryos. In combination with preactivated oocytes which
are characterized by low MPF activity, nuclei from all
stages of the cell cycle can support the development of
normoploid embryos [Campbell et al., 1996a]. The molec-
ular mechanisms underlying nuclear reprogramming are
only partially known. The process involves a switch-off of
transcription, modifications of the chromatin and again a
start of transcription. Nuclei late in G2, in M, in early G2
or in G0 seem to be more amenable to reprogramming
than nuclei in other stages of the cell cycle. This may be
due to a number of features, such as chromatin condensa-
tion, removal of transcription factors etc. Empirical data
suggest that every mitotic division before the onset of
transcription is positive for successful re-programming of
the donor nucleus. The onset of transcription is at the 2-
cell stage in mouse, the 4-cell stage in pig, the 8-cell stage
in sheep and cow, and at a stage of 4,000 cells in the frog.
This may explain the high efficiency of nuclear transfer in
ruminants as compared to pig and mouse.
The second part of the talk summarized applications of
somatic cell nuclear transfer, particularly the cloning of
transgenic farm animals from transfected cells which was
first demonstrated by the generation of human factor IX
transgenic sheep [Schnieke et al., 1997]. The major ad-
vantages as compared to classical DNA-microinjection
technique are a reduction in costs and animals required.
Furthermore, the time to set up a production herd is
reduced from 44 to 18 months and from 78 to 33 months
in sheep and cow, respectively. Another advantage is the
possibility of introducing targeted mutations in cultured
cells. At PPL, gene targeting in cultured fetal fibroblasts
was successful in 9% of the selected clones.
Jose B. Cibelli presented a similar cost-efficiency cal-
culation for the DNA-microinjection vs. the nuclear
transfer technique of gene transfer. However, he pointed
out the high incidence of abnormalities of pregnancies
and calves derived from nuclear transfer. The alterations
observed include placentomas which are enlarged but
reduced in number and hydrallantois, and fatty liver and
heart abnormalities in the born offspring. Nevertheless,
his group was the first to produce transgenic cattle by
nuclear transfer from nonquiescent fetal fibroblasts [Ci-
belli et al., 1998a]. Fetal fibroblasts have been successfully
used for nuclear transfer after up to 30–35 population
doublings. In addition, transgenic bovine chimeras were
produced by reintroduction into preimplantation em-
bryos of ES-like cells which were derived by nuclear trans-
fer from transfected fetal fibroblasts [Cibelli et al., 1998b].
The feasibility of using cells from transgenic cloned bo-
vine fetuses for therapy has been demonstrated by im-
proved performance of a rat model of Parkinson’s disease
following transplantation of these cells into immunosup-
pressed animals [Zawada et al., 1998]. However, for cell
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therapy, selection of a pure population of a specific cell
type is essential. This can be achieved, in principle, by
transfecting cells with a selectable marker gene that is
active only in the desired cell type.
The third topic of the meeting was devoted to ‘Stem
cell differentiation – Cell therapy’. The capacity of ES
cells to differentiate under appropriate conditions into a
broad spectrum of cell types and to generate multiple
lineages in culture may be used in the future for human
tissue repair. In this context, no single cell or universal
donor is likely to be useful as cellular graft for all diseases.
Different sources, i.e. ES cells vs. stem cells from the bone
marrow or fetal brain are potential cell types to be used in
somatic cell therapy.
As first speaker of the session, Oliver Brüstle (Univer-
sity of Bonn, Germany) reported on ‘Transplantation of
embryonic stem cell-derived neuronal precursors’. He
used mouse ES cells to differentiate them into precursors
for oligodendrocytes and astrocytes. Glial precursor cells
were transplanted into the spinal cord of myelin-deficient
rats, an animal model for the hereditary human myelin
disorder Pelizaeus-Merzbacher disease. ES cell-derived
precursors integrated, interacted with host neurons, and
efficiently myelinated axons in brain and spinal cord
[Brüstle et al., 1999]. Together with earlier reports on
using ES cell-derived cardiac cells (selected by a myosin
heavy chain promoter-neomycin phosphotransferase con-
struct) [Klug et al., 1996], these data showed that ES cells
indeed have the potential to serve as a valuable source of
cell type-specific somatic precursor (i.e. neuronal) or dif-
ferentiated (i.e. cardiac) cells for tissue repair.
The characterization of pluripotent hematopoietic pro-
genitor cells of different sources for transplantation and
gene therapy was the main topic of the lecture given by
Anthony D. Ho (University of Heidelberg, Germany).
CD34+ cells from fetal liver, fetal bone marrow, umbilical
cord blood, adult bone marrow, and mobilized peripheral
blood were sorted and cultured as single cells. The
CD34+/CD38–/HLA–DR+ subset contained the highest
number of candidate stem cells among the various immu-
nophenotypes. Fetal liver contained the highest propor-
tion of CD34+ cells (11.4%) and the highest level of
CD34+/CD38–/HLA–DR+ subsets (34.7%) among cells
from various ontogenic ages. Therefore, cells from the
fetal liver appeared to represent the best source for ex vivo
stem cell expansion and genetic manipulation [Huang et
al., 1998].
Another important aspect of stem cell properties with
respect to cell transplantation is the asymmetry of cell
divisions. Using time lapse and fluorescence imaging it
was possible to monitor the divisional history of distinct
progenitor cells. Asymmetric divisions were found to
occur in pluripotent hematopoietic stem cells. One of the
important tasks in the stem cell field is to identify the reg-
ulatory molecules responsible for asymmetric divisions
generating differentiated and self-renewal stem cell popu-
lations.
In his closing lecture, Axel Haverich (University of
Hannover, Germany) summarized the requirements for
cell, tissue or organ transplantations. Because of possible
endogenous retrovirus contaminations, xenotransplanta-
tion is restricted in human transplantation therapy.
Therefore, efforts are directed to allogenic and autologous
tissue grafts [Gage, 1998]. Allogenic transplantation by
using ES cell-derived cells would require the genetic ma-
nipulation of histocompatibility [Rathjen et al., 1998].
Autologous transplantation would, in principle, require
the nuclear transfer of ‘individual’ human somatic cells
into enucleated oocytes, further development into blasto-
cysts, ES cell generation and differentiation into somatic
cells [Cibelli et al., 1998b; Prelle et al., 1999]. These ‘indi-
vidualized’ somatic cells would create the principal source
for autologous tissue grafts using ES cells [Wilmut, 1998;
Boheler and Fiszman, 1999; Solter, 1999]. However, up to
now, the state of knowledge and the ethical and social
implications do not justify experiments using human em-
bryos [Shapiro, 1999]. Before any use of the cloning tech-
nology for human cell therapy will be possible, further
research including animal models and stem cell differenti-
ation approaches in culture (i.e. identification of differen-
tiation factors, selective differentiation strategies, report-
er gene assays) is necessary to understand the basic princi-
ples of pluripotent stem cell differentiation and the mech-
anisms involved in reprogramming somatic cell nuclei.
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